Shanghai InnoStar Bio-tech Co., Ltd. (SHA:688710)
China · Delayed Price · Currency is CNY 56.80
-1.80 (-3.07%)
At close: Feb 2, 2026
SHA:688710 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Operating Revenue | 828.94 | 1,141 | 1,036 | 862.21 | 581.62 | 333.77 |
Other Revenue | 0.99 | 0.99 | 2.02 | 0.86 | 0.15 | 0 |
| 829.92 | 1,142 | 1,038 | 863.07 | 581.77 | 333.77 | |
Revenue Growth (YoY) | -26.03% | 9.94% | 20.32% | 48.35% | 74.30% | 36.36% |
Cost of Revenue | 653.9 | 807.21 | 628.19 | 535.88 | 362.59 | 205.13 |
Gross Profit | 176.02 | 334.46 | 410.24 | 327.2 | 219.18 | 128.64 |
Selling, General & Admin | 143.53 | 144.89 | 165.38 | 168.11 | 118.78 | 67.23 |
Research & Development | 55.37 | 58.31 | 58.23 | 49.51 | 26.81 | 18.79 |
Other Operating Expenses | 3.41 | 1.84 | -3.41 | -32.06 | -37.04 | -9.96 |
Operating Expenses | 205.87 | 209.37 | 221.68 | 190.26 | 112.28 | 76.59 |
Operating Income | -29.85 | 125.09 | 188.56 | 136.94 | 106.9 | 52.05 |
Interest Expense | -9.74 | -11.67 | -12.01 | -13.42 | -10.99 | -0.47 |
Interest & Investment Income | 18.08 | 21.52 | 20.16 | 17.83 | 6.21 | 3.57 |
Currency Exchange Gain (Loss) | 0.78 | 0.78 | -0.37 | - | - | - |
Other Non Operating Income (Expenses) | 0.05 | -0.17 | -0.2 | 1.33 | -0.14 | 1.47 |
EBT Excluding Unusual Items | -20.68 | 135.55 | 196.14 | 142.68 | 101.98 | 56.63 |
Gain (Loss) on Sale of Assets | 19.28 | -0 | -0 | 0.21 | - | - |
Asset Writedown | -6.87 | - | - | -1.1 | -0 | 0 |
Other Unusual Items | 22.31 | 23.26 | 15.55 | - | - | - |
Pretax Income | 14.04 | 158.81 | 211.68 | 141.79 | 101.98 | 56.63 |
Income Tax Expense | -2.74 | 22.26 | 30.17 | 23.64 | 9.5 | 8.12 |
Earnings From Continuing Operations | 16.78 | 136.55 | 181.52 | 118.16 | 92.48 | 48.51 |
Minority Interest in Earnings | -16.58 | 11.23 | 12.93 | 17.25 | 2.21 | - |
Net Income | 0.2 | 147.78 | 194.45 | 135.41 | 94.69 | 48.51 |
Net Income to Common | 0.2 | 147.78 | 194.45 | 135.41 | 94.69 | 48.51 |
Net Income Growth | -99.86% | -24.00% | 43.60% | 43.01% | 95.21% | 34.11% |
Shares Outstanding (Basic) | 146 | 117 | 106 | 97 | 73 | 59 |
Shares Outstanding (Diluted) | 146 | 117 | 106 | 97 | 73 | 59 |
Shares Change (YoY) | 34.12% | 10.98% | 9.26% | 31.77% | 24.09% | -0.23% |
EPS (Basic) | 0.00 | 1.26 | 1.84 | 1.40 | 1.29 | 0.82 |
EPS (Diluted) | 0.00 | 1.26 | 1.84 | 1.40 | 1.29 | 0.82 |
EPS Growth | -99.90% | -31.52% | 31.43% | 8.53% | 57.32% | 34.43% |
Free Cash Flow | -174.37 | -384.15 | -65.85 | 132.67 | 44.33 | 0.5 |
Free Cash Flow Per Share | -1.20 | -3.27 | -0.62 | 1.37 | 0.60 | 0.01 |
Dividend Per Share | 0.320 | 0.320 | - | - | 0.350 | 0.170 |
Dividend Growth | - | - | - | - | 105.88% | - |
Gross Margin | 21.21% | 29.30% | 39.51% | 37.91% | 37.67% | 38.54% |
Operating Margin | -3.60% | 10.96% | 18.16% | 15.87% | 18.38% | 15.60% |
Profit Margin | 0.03% | 12.94% | 18.73% | 15.69% | 16.28% | 14.53% |
Free Cash Flow Margin | -21.01% | -33.65% | -6.34% | 15.37% | 7.62% | 0.15% |
EBITDA | 18.55 | 172.99 | 235.8 | 179.75 | 139.95 | 75.26 |
EBITDA Margin | 2.23% | 15.15% | 22.71% | 20.83% | 24.05% | 22.55% |
D&A For EBITDA | 48.4 | 47.9 | 47.24 | 42.82 | 33.05 | 23.21 |
EBIT | -29.85 | 125.09 | 188.56 | 136.94 | 106.9 | 52.05 |
EBIT Margin | -3.60% | 10.96% | 18.16% | 15.87% | 18.38% | 15.60% |
Effective Tax Rate | - | 14.02% | 14.25% | 16.67% | 9.32% | 14.34% |
Revenue as Reported | 829.92 | 1,142 | 1,038 | 863.07 | - | - |
Advertising Expenses | - | 1.14 | 1.84 | 0.34 | - | - |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.